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Abstract
The role of the ATP binding cassette transporter A1 (ABCA1) in maintaining cellular lipid homeostasis in
cardiovascular disease is well established. More recently, the important beneficial role played by ABCA1 in
modulating pathogenic disease mechanisms, such as inflammation, in a broad range of chronic conditions has
been realised. These studies position ABCA1 as a potential therapeutic target in a diverse range of diseases where
inflammation is an underlying cause. Chronic respiratory conditions such as asthma and chronic obstructive
pulmonary disease (COPD) are driven by inflammation, and as such, there is now a growing recognition that we
need a greater understanding of the signaling pathways responsible for regulation of ABCA1 expression in this
clinical context. While the signaling pathways responsible for cholesterol-mediated ABCA1 expression have been
clearly delineated through decades of studies in the atherosclerosis field, and thus far appear to be translatable to
the respiratory field, less is known about the cholesterol-independent signaling pathways that can modulate ABCA1
expression in inflammatory lung disease. This review will identify the various signaling pathways and ligands that
are associated with the regulation of ABCA1 expression and may be exploited in future as therapeutic targets in the
setting of chronic inflammatory lung diseases.
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Background
ATP binding cassette transporter A1 (ABCA1) is a trans-
membrane transporter protein ubiquitously expressed in
human tissue, and found in abundance in the liver and
lungs (reviewed in [1]). While its primary role is to main-
tain lipid homeostasis by controlling the efflux of cellular
cholesterol and phospholipids, ABCA1 is increasingly
recognised as having anti-inflammatory functions in a
diverse range of diseases where inflammation is an under-
lying pathogenic mechanism (reviewed in [1–4]). Thus,
given the role played by ABCA1 in suppressing inflamma-
tion, understanding the signaling pathways that regulate
ABCA1 expression may provide potential therapeutic
strategies to maintain cholesterol homeostasis and treat
conditions with excessive inflammation in the future.
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ABCA1-mediated cholesterol efflux
ABCA1 transporter plays an important role in maintain-
ing cellular cholesterol homeostasis by participating in the
reverse cholesterol transport pathway (RCT) [5]. ABCA1
expressed in peripheral cells facilitates the export of
cellular cholesterol to its extracellular acceptor protein
apolipoprotein-A1 (apoA-1) [6]. In macrophages, ABCA1
interacts with apoA-1 to develop nascent high density
lipoprotein (HDL) before interacting with ATP binding
cassette transporter G1 (ABCG1) and scavenger receptor
class B type 1 to from mature HDL particles [7]. Subse-
quently, HDL transports the cholesterol from peripheral
tissues to the liver for excretion [6].
Altered ABCA1 expression in lung diseases
Mutations in ABCA1 can cause Tangier disease, a rare
genetic disorder characterized by a substantial reduction
in HDL levels [8]. Studies investigating the roles of
ABCA1 in RCT have since observed similarities in the
phenotype of ABCA1 deficient mice compared to the
phenotype of human Tangier disease [9, 10]. The pheno-
type of ABCA1-knockout mice macrophages in vivo
included lipid accumulation and significantly reduced
HDL and apoA-1 levels [9]. Lipid accumulation as a
result of reduced HDL and apoA-1 in ABCA1 and
ABCG1 knockout mice macrophages was found to
induce increased circulating pro-inflammatory cytokines,
displaying signs of systemic inflammation [9, 10]. In
addition, while similar outcomes were found in vitro
with the knockdown of ABCA1 in human macrophages,
ABCG1 expression was increased [11].
Evidence from both in vitro and in vivo studies have
shown ABCA1 expression is altered in lung diseases
such as COPD [12, 13]. In a recent study, Sonett et al.
found that the expression of ABC transporters (ABCA1
and ABCG1) in lungs of patients with moderate to se-
vere COPD to be significantly downregulated compared
to healthy lungs [12]. In addition, greater downregula-
tion of ABCA1 expression was observed compared to
ABCG1 indicating that the importance of ameliorating
downregulated ABCA1 may outweigh downregulated
ABCG1 [12]. Cigarette smoke is proposed as the primary
cause of downregulated ABCA1 expression in patients
with COPD [12]. There is also evidence that cigarette
smoke modulates the signaling pathways that regulate
ABCA1 expression in macrophages in vitro and in vivo
[12, 14]. Pulmonary abnormalities in ABCA1 expression
have also been found in pneumonia caused by chlamydia
pneumoniae bacteria [13, 15]. Chlamydia pneumoniae
infection was demonstrated to affect cholesterol traffick-
ing, associated with accelerating intracellular cholesterol
accumulation by downregulating ABCA1 expression in
mice models in vivo and human macrophage and lung
epithelial cells in vitro [13, 15, 16]. However, the exact role
of ABCA1 in the pathogenesis of respiratory infection is
currently unknown.
ABCA1, cholesterol homeostasis and the link with
inflammation
Cellular cholesterol is linked with numerous inflamma-
tory functions of the lungs [17]. Hence, the proteins
involved in the process of RCT may impact the inflam-
matory responses elicited by overloading of free choles-
terol in macrophages [18]. Understanding the functions
of ABCA1 and HDL may reveal the impact of regulating
cholesterol on inflammatory functions in lungs. In
addition to HDL’s role in RCT, HDL assists with the
production of surfactant in alveolar type II cells [19], a
critical cell type in COPD. Furthermore, it is known that
when ABCA1 is repressed, excess cholesterol builds up
in alveolar cells, damaging surfactant function and
increasing the inflammatory response which has been
implicated in the pathogenesis of chronic obstructive
pulmonary disease (COPD), asthma and other lung
diseases (reviewed in [1, 17, 20]).
Considering the relationship between cholesterol
homeostasis and airway inflammation, the therapeutic
focus has been on reducing intracellular cholesterol
synthesis using cholesterol-lowering drugs, like statins
[17]. There have been large clinical trials, including
STATCOPE, that have tested the effectiveness of sta-
tin treatment on patients with COPD [21, 22]. Des-
pite the benefits that were observed in prior
retrospective studies, STATCOPE observed no thera-
peutic benefit from statin treatment in patients with
COPD [21, 23, 24]. This would suggest that a differ-
ent approach to restoring cholesterol balance, perhaps
through alternative targets that have the potential to
modulate cholesterol, and repress inflammation at the
same time, such as ABCA1, warrant further investiga-
tion. This is the focus of this review.
Most studies exploring the role and function of
ABCA1 have been conducted in cholesterol associated
disease states such as atherosclerosis [25]. Athero-
sclerosis was traditionally known as a cholesterol stor-
age disease [26]. However, it is now recognised as a
chronic inflammatory disease, with evidence of excess
cholesterol accumulation promoting inflammatory re-
sponses [27, 28]. There are a number of lines of evidence
from clinical and preclinical studies that link atherosclerosis
and inflammation. An earlier study using mice models
showed that inhibiting the expression of inflammatory me-
diators significantly improves the severity of atherosclerosis
[29]. Patients with atherosclerosis are identified by high
levels of low density lipoproteins (LDL) cholesterol in
their body [30]. Regulation of LDL cholesterol homeo-
stasis affects the innate immune system [31]. This is
shown by LDL cholesterol inducing pro-inflammatory
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cytokines through activation of the toll-like receptor (TLR)
pathways [32, 33]. This has led the research focus to shift
towards looking at the anti-inflammatory benefits of
ABCA1 in atherosclerosis. ABCA1 may also exert direct
anti-inflammatory actions [34, 35] that are independent of
its impact on cholesterol homeostasis, although given the
central role of cholesterol in cell survival, this independence
may prove difficult to tease out.
Nevertheless, growing evidence has clearly impli-
cated ABCA1 as a target of interest in diseases typified
by inflammation. The potential anti-inflammatory ef-
fects of ABCA1 have thus led to increasing interest to-
wards investigating the benefit of ABCA1 in
inflammatory lung diseases [12, 36]. While it is well
recognised that cholesterol exerts significant regula-
tory control over ABCA1 expression, less well under-
stood is the impact that inflammatory mediators
themselves have on ABCA1 upregulation. Given the inter-
action between cholesterol homeostasis and pulmonary in-
flammation, the linkage represents a feasible option for
therapeutic intervention with the potential to have benefi-
cial effects in both atherosclerosis and COPD; two chronic
conditions that are a common comorbidity. To highlight
these potential therapeutic interactions, the aim of this re-
view is to explore the molecular mechanisms responsible
for ABCA1 expression. Notably, ABCA1 expression can be
regulated via cholesterol-dependent and -independent
mechanisms and the aim of the review is to explore these
signaling pathways in the context of respiratory disease.
Regulation of ABCA1 expression: cholesterol-dependent
signaling pathways
Cholesterol homeostasis is maintained through feed-
forward and feed-back mechanisms involving ABCA1
and other partners. Notably, ABCA1 expression is
regulated through key signaling pathways mediated by
excess cholesterol (Fig. 1), which will be described
briefly below.
LXR/RXR pathway
Cholesterol in cells can be converted into oxysterols,
which in turn can potently upregulate ABCA1 expression
[4]. In cell types with relevance to inflammatory lung
diseases (including macrophage, epithelial and smooth
muscle cells (Table 1) [4, 35, 40–43]), the predominantly
reported oxysterol is 25-hydroxycholesterol (25-HC). This
naturally occurring stimulus increases the expression of
ABCA1 through activation of liver X receptor (LXR) path-
way [44, 45]. LXR forms a heterodimer with retinoid X re-
ceptor (RXR), and together they form a transcription
factor that binds to the promoter element in the ABCA1
gene to increase expression and ultimately the upregula-
tion of ABCA1 protein expression [44, 45], amongst other
targets. Transcription occurs upon influx of excess intra-
cellular cholesterol, however cholesterol does not directly
activate this pathway but is converted to 25-HC [46].
While oxysterols are the ligands that activate LXR/RXR to
increase ABCA1 expression, cholesterol loading triggers
the increase in oxysterol production downstream of the
mevalonate pathway to initiate increasing transcription of
ABCA1 gene [47, 48]. Specific oxysterols can be produced
de novo in the mevalonate pathway, independent of the
common cholesterol derived oxysterol [49]. Cholesterol in
humans is predominately synthesized de novo by the liver,
initiated by acetyl coenzyme 3-hydroxy-3-methyl-glutaryl-
coenzyme [50]. 24(S),25-epoxycholesterol (24,25EC) is
such an example, where it is produced from acetyl coen-
zyme during a gap in the mevalonate pathway [51]. Simi-
lar to other oxysterols, 24,25EC has since shown in studies
to activate LXR receptors [52].
Given the important role played by LXR in this path-
way, it follows that a potential therapeutic target to
modulate cholesterol homeostasis is by increasing
ABCA1 expression through the LXR dependent pathway
[41]. To this end, a series of synthetic LXR agonists have
been developed that are able to significantly increase
ABCA1 expression [42]. However LXR agonist treatment
outcomes have been varied with reports of adverse off-
Table 1 Currently known effects of clinical and experimental drugs on ABCA1 expression in cells in vitro
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target effects, including increased fatty acid, triglyceride
synthesis and hepatic steatosis [53–55]. Recently, there
has been increasing interest in the possibility that LXRα,
an isoform of LXR, is the primary cause for adverse ef-
fects of conventional LXR ligands [56]. This has created
interest in the development of LXRβ-specific drugs that
are thought not to generate such adverse effects.
SREBP-2 pathway
Another pathway involved in the regulation of cellular
cholesterol homeostasis is mediated by the sterol regula-
tory element binding protein 2 (SREBP-2) transcription
factor [44]. SREBP-2 regulates ABCA1 independently of
the LXR pathway, and, unlike the LXR pathway activation,
SREBP-2 activation can decrease ABCA1 expression [46,
56, 57]. SREBP-2 activation is dependent on the SREBP
cleavage activating protein (SCAP) protein, which has a
sterol sensing domain capable of sensing cellular choles-
terol levels [46]. When intracellular cholesterol levels are
low, SCAP escorts SREBP-2 to the Golgi for activation
before being translocated to the sterol regulatory element
(SRE) in the nucleus to promote transcription of different
target genes as well as SREBP-2 itself [33]. Located within
intron 16 of SREBP-2 is microRNA-33a (miR-33a), which
is co-transcribed with SREBP-2 [33, 58]. The miR-33a
has been shown to inhibit ABCA1 expression in mice
Fig. 1 ABCA1 cell signaling pathways. The cholesterol-dependent signaling pathways which regulate ABCA1 include the LXR/RXR and SREBP-2
pathway. These two pathways are activated in response to changes in intracellular cholesterol levels by oxysterols and SREBP-2 molecules which
target the transcriptions factors, LXR/RXR and SREBP-2, respectively. The cholesterol-independent signaling pathways associated with ABCA1
regulation include the NF-κB, TLR4/Myleoid88, JAK2/STAT3, cAMP/PKA, apoptosis pathways involved in regulating inflammatory responses
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pancreatic islets ex vivo and human macrophages
in vitro [58–60]. Recently, it has been demonstrated
that inhibition of miR-33a in mice hepatic tissue and
macrophages in vivo leads to an increased expression of
the miR-33a target gene ABCA1 [61, 62]. Increasing
ABCA1 expression by inhibiting miR-33a allows ABCA1
target treatment to bypass the adverse effects of current
treatments that activate the LXR pathway [62].
Regulation of ABCA1 expression: cholesterol-independent
signaling pathways
Recent investigations have revealed that a number of
inflammatory mediators and noxious exposures (such as
cigarette smoke) that drive lung disease also have an im-
pact on ABCA1 expression. Clinically-used and experi-
mental drugs also target ABCA1, with some key in vitro
studies performed in cells with relevance to respiratory
disease listed in Table 1. These changes to ABCA1 ex-
pression are regulated by signaling (Fig. 1) (as detailed
below), some of which are subject to cross-talk.
TNF
Tumour Necrosis Factor (TNF) is a proinflammatory
cytokine that is highly expressed in patients with COPD
[63]. TNF is known to activate many signaling pathways
of which some have previously shown to induce changes
in ABCA1 expression [64]. These pathways include the
nuclear factor-κB (NF-κB), sterol regulatory element
binding protein 2 (SREBP-2) and janus kinase 2/signal
transducer 3 (JAK2/STAT3) [65–67]. With numerous
pathways and molecular partners involved, studies have
shown that TNF stimulation can result in different
impacts on ABCA1 expression depending on the cell line
[4, 16, 39, 68]. For example, TNF stimulation can increase
ABCA1 expression via the canonical NF-κB pathway [69].
However, activation of NF-κB induced by TNF also upre-
gulates the mRNA levels of miR-33a by targeting its host
gene SREBP-2 in macrophages in vitro and mice in vivo
[58]. As increased expression of miR-33a is associated
with repressed ABCA1 expression, increasing TNF in this
context will result in decreased ABCA1 expression [70].
We have recently shown that TNF increases ABCA1 pro-
tein upregulation in BEAS-2B epithelial cells in vitro [4],
however to date, the molecular mechanisms for these
findings are unknown. Interestingly, studies performed in
parallel in another lung epithelial cell line, A549 in vitro,
indicated that TNF did not increase ABCA1 protein in
these cells [4]. Perhaps the difference in impact of TNF on
ABCA1 within the two lung epithelial cell lines, used com-
monly as cellular models of respiratory inflammation, are
the different contribution of miR-33a or other known
ABCA1 regulators. Further studies are warranted to estab-
lish the mechanisms involved.
TLR4/Myeloid88 pathway
Toll like receptor 4 (TLR4) is a primary source of innate
immune system defence [71]. This protein is expressed
in macrophages and lung bronchial epithelial cells, two key
cell types driving airway inflammation [72]. The major
cause of airway inflammation in patients with COPD is
cigarette smoke [72]. Notably, cigarette smoke exposure
(CSE) results in an increase in lipopolysaccharide (LPS)-in-
duced TLR4 expression shown in primary small airway
epithelial cells in vitro and mice in vivo [72, 73]. The LPS
dependent increase in TLR4 activates its downstream
adaptor molecule Myeloid88 that transduces TLR4 signal-
ing to the NF-κB inhibitor, IκBα [74]. Phosphorylation of
IκBα allows NF-κB to translocate into the nucleus [75],
ultimately activating inflammatory genes responsible for
encoding proinflammatory cytokines like TNF, while also
promoting the expression of miR33a which reduces
ABCA1 expression [69, 76]. The effect of cigarette smoke
on the TLR4/Myeloid88 pathway was explored by exposing
human macrophage THP-1 cells in vitro and mice macro-
phages in vivo to CSE [10, 12, 14]. The results showed that
ABCA1 expression was significantly downregulated by
CSE exposure in vitro and in vivo [10, 12, 14].
cAMP/PKA pathway
The cyclic adenosine monophosphate (cAMP)/protein kin-
ase A (PKA) pathway is responsible for regulating multiple
cellular functions, including anti-inflammatory responses
[53]. Activation of cAMP/PKA pathway reduces inflamma-
tion by inhibiting NF-κB, preventing the reduction of
ABCA1 and increased pro-inflammatory cytokines caused
by NF-κB [69, 77]. ABCA1 expression is also regulated
both transcriptionally and post-translationally by the
cAMP/PKA pathway [55]. Transcriptionally, cAMP in-
duces an increase in ABCA1 expression and its mediated
reverse cholesterol transport [55, 78]. Prior studies have
shown that stimulating human fibroblasts in vitro and
murine macrophages in vivo with a 8-bromo-cAMP analog
activated the cAMP/PKA pathway [8, 79]. Early studies
performed on human macrophages were, however, unable
to show a significant increase in ABCA1 expression via
activation of the cAMP/PKA pathway [40, 80, 81]. In
contrast, a recent study performed by Liao et al. showed
that stimulating human THP-1 macrophage cells with
intermedin, a calcitonin family peptide, significantly in-
creased ABCA1 expression and cholesterol efflux through
the cAMP/PKA pathway [23]. It is important to note that
the impact of cAMP on ABCA1 expression depends on
the species used for the study, as there are key differences
in the 5′-promoter element of the murine and human
ABCA1 gene whereby the functional cAMP response
element (CRE) in murine ABCA1 gene promoter is not
present in the first intron of the human promoter [82, 83].
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However, while transcriptional regulation differs, cells
from both human and mice are responsive to cAMP, al-
beit via dissimilar mechanisms. Post-translationally, the
upregulation of ABCA1 phosphorylation and cholesterol
efflux in this signaling cascade is initiated when apoA-1
interacts with ABCA1 during the process of reverse
cholesterol transport [78]. The interaction between
apoA-1 and ABCA1 activates heterotrimeric G proteins
and adenylyl cyclase to produce cAMP, consequently
activating PKA, a direct downstream target of cAMP
[43, 78, 84]. PKA then increases phosphorylation of
ABCA1, which has been shown by previous studies to
significantly increase ABCA1 expression and cholesterol
efflux in macrophage cells [78, 85]. Whether upregulation
of ABCA1 by the cAMP/PKA pathway occurs in the
context of inflammatory lung diseases warrants further
investigation, especially since cAMP-elevating agents (e.g.
β2-adrenergic receptor agonists and phosphodiesterase in-
hibitors) are widely used treatments in respiratory medicine
today.
JAK2/STAT3 pathway
Signal transducer and activator of transcription 3
(STAT3) plays a complex role in regulating inflamma-
tion that occurs with airway injury [86]. Cigarette smoke
is associated with the occurrence of airway injury and in-
flammation, and can also activate STAT3 in the lungs
[86, 87]. While the exact role of STAT3 in inflammatory
lung diseases is relatively poorly understood, it is known
that the absence of STAT3 expression impairs the innate
anti-inflammatory response of the lungs [86], suggesting
that the presence of STAT3 is important in reducing
lung inflammation. Thus far, evidence has shown that
STAT3 activation as a result of ABCA1 and apoA-1
interaction produces an anti-inflammatory effect [88].
Similar anti-inflammatory effects were shown by pro-
inflammatory cytokines, interleukins and interferons activa-
tion of the janus kinase 2 (JAK2)/STAT3 pathway [89, 90].
A known cytokine that activates this pathway is interleukin
6 (IL-6), with IL-6 expression promoted by inflammatory
markers of COPD like TNF [89, 91]. The initial signaling
molecule which is activated upon apoA-1 and ABCA1
interaction or by IL-6 cytokine is JAK2 [88, 92]. Upon acti-
vation of JAK2, it undergoes autophosphorylation, before
phosphorylating its downstream target STAT3 [92, 93]. In
human and mouse macrophages, phosphorylated STAT3
binds onto the CRE site located on the first intron of the
human and murine ABCA1 gene to increase the gene
expression of ABCA1 [90, 94].
Apoptosis increases ABCA1 expression
During acute and chronic airway inflammation there is
a significant increase in immune and structural cells
that undergo apoptosis [95]. The clearance of cell
apoptosis in the lungs is primarily regulated by airway
macrophages in a process called efferocytosis [95].
Apoptotic cells have previously been shown to be dir-
ectly associated with an increase in ABCA1 expression
in macrophages [96, 97]. Apoptotic cells contain phos-
phatidylserine (PtdSer) that acts like a recognition sig-
nal for phagocytes, binding onto cell surface receptors
on macrophages, like mer tyrosine kinase (MerTK)
[95, 97]. During efferocytosis regulated by MerTK in
pulmonary tissue, the LXR pathway is activated; thus
expression of ABCA1 is upregulated [90]. With the
increased apoptosis that occurs in inflammatory lung
diseases like COPD, the likely corollary is that ABCA1
expression should be increased; however, this prediction
does not hold true because the process of efferocytosis in
patients with COPD is dysregulated [98]. The exact mech-
anism underlying the defect of efferocytosis in COPD is un-
known, however, it is speculated to be linked to alterations
in expression and function of the PtdSer receptors such as
MerTK [95, 99]. Hence, additional studies exploring the
molecular mechanisms behind dysregulated efferocytosis in
COPD are needed to identify what the potential effect of
functional alterations in MerTK has on ABCA1 expression.
Recent studies have reported a pathway regulated by
the phagocytic receptor brain specific angiogenesis
inhibitor 1 (BAI1), operates in a similar manner to the
way in which MerTK recognises the PtdSer on apoptotic
cells [100]. In brief, BAI1 activates its downstream
signaling mediator Ras-related C3 botulinum toxin sub-
strate 1 (RAC1) upon contact with PtdSer to promote
ABCA1 transcription independent of the LXR pathway
[100]. It is currently unclear whether this pathway is
present in pulmonary tissue. Thus, further studies exam-
ining the effect of apoptosis on ABCA1 expression in
lung macrophages are warranted.
ApoA-1 interaction with ABCA1
ApoA-1 is an acceptor for cellular cholesterol from per-
ipheral cells that directly interacts with ABCA1 to forms
nascent lipid-poor HDL [101]. Murphy et al. showed
that HDL formed from the interaction between apoA-1
and ABCA1 had anti-inflammatory effects [102]. It is
likely that the anti-inflammatory properties of apoA-1
are directly associated with regulation of the ABCA1 sig-
naling pathways, cAMP/PKA and JAK2/STAT3 [78, 88].
As outlined above, both of these signaling pathways are
known to upregulate ABCA1 expression, with increased
ABCA1 expression correlated with increase in HDL [20].
The signaling pathways involved with the regulation of
ABCA1 expression are hence key in mediating the anti-
inflammatory properties of HDL.
Intriguingly, apoA-1 represses LPS-induced proinflam-
matory cytokine production via the TLR4/myeloid88
pathway in macrophages [34]. This was linked to
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reduction in mRNA stability of proinflammatory media-
tors through the actions of the destabilising RNA binding
protein, tristetraprolin (TTP) [34]. While it is unclear as
to the exact mechanism by which the interaction between
ABCA1 and apoA-1 induce the TTP-mediated anti-
inflammatory effect, Yin et al. reported that the effect
of apoA-1 on TTP was significantly diminished when
ABCA1 expression was silenced [34]. Taken together,
these studies underscore the promise of ApoA-1 as a
beneficial target in respiratory disease. However, the
cost of purified apoA-1 and recombinant apoA-1 may
prove prohibitive to further investigation. Synthetic
analogs of apoA-1, known as apoA-1 mimetics, have
been developed that offer a cost-effective solution
[103]. Excitingly, ApoA-1 mimetics 5A and 4F adminis-
tered intravenously and intratracheally have been shown to
exhibit anti-inflammatory and antioxidant effects in human
coronary artery cells in vitro and mice in vivo through
interaction with ABCA1 [103, 104]. Further investigations
are warranted.
Effect of current medications in pulmonary diseases on
ABCA1 expression
Current pharmacological treatments for people with re-
spiratory disease include the use of corticosteroids,
bronchodilators (such as β2-adrenergic receptor agonist)
and phosphodiesterase inhibitors. Although some studies
have examined the impact of current respiratory medica-
tions on ABCA1 expression, there is much scope for
further investigation. The effect of these medicines on the
signaling pathways regulating ABCA1 expression will be
outlined below.
Corticosteroids
To date, there have been limited studies aimed at examin-
ing the effect of steroids on ABCA1 expression. While
there is no evidence of a glucocorticoid response element
in the ABCA1 promoter, non-cis mediated transcriptional
regulation of ABCA1 has been shown to exist in macro-
phages [105, 106]. The steroid dexamethasone decreased
ABCA1 expression through a LXR-independent pathway
in macrophages in vitro [106].
Bronchodilators
β2-adrenergic receptor agonists are commonly used
bronchodilators for treating lung diseases such as COPD
or asthma [107]. The mechanism by which β2-agonists
promote bronchodilator effects in the lungs is thought
to occur via cAMP/PKA-dependent reduction in intra-
cellular calcium [108], although other pathways may
exist. Activation of the cAMP/PKA pathway is the result
of increased intracellular cAMP after β2-agonists treat-
ment [109]. As outlined in a previous section, it has been
established that cAMP induces upregulation of ABCA1
expression in human macrophages [110]. Thus, in
addition to the bronchodilator effects of β2-agonists
treatment, anti-inflammatory properties of β2-agonists
may be associated with ABCA1 mediated suppression of
inflammatory responses in the lungs.
Phosphodiesterase inhibitors
Type 4 phosphodiesterase (PDE4) inhibitors are a treat-
ment option in COPD. Similar to the effect of β2-ago-
nists, PDE4 inhibitors exhibit multiple benefits which
include reducing inflammation and eliciting airway
smooth muscle relaxation via the cAMP/PKA pathway
[18]. The PDE4 selective inhibitor, rolipram, has been
shown to increase intracellular cAMP which upregulates
ABCA1 expression and apoA-1-mediated cholesterol
efflux in mouse and human macrophages [111].
ABCA1 as an alternative biological target for the
treatment of lung inflammation
Statins
Statins were postulated as possible treatment for inflam-
matory lung diseases including COPD. However, clinical
trials like STATCOPE were shown to have an overall in-
significant impact on patient outcomes [21, 112, 113].
Previous studies have looked at whether the reason be-
hind the statins’ inability to significantly reduce inflam-
mation during pulmonary exacerbation is linked with
ABCA1 being downregulated as a result of statin treat-
ment [1, 4, 37]. We recently showed that in human lung
epithelial cell lines in vitro, both simvastatin and atorva-
statin did not significantly impact on ABCA1 expression
(Table 1) [4]. In human macrophage cells in vitro, how-
ever, Niesor et al. showed that simvastatin and atorvastatin
reduced ABCA1 expression and increased miR33, support-
ing the possibility that a repressive effect on ABCA1-
mediated anti-inflammatory functions could have played a
role in the equivocal outcomes shown in STATCOPE [37].
It is plausible that the different results in these cell lines
were due to cell type specificity. Hence, by testing this hy-
pothesis on other pulmonary cell lines, like airway smooth
muscle cells, we would improve our understanding of the
effect of statins on ABCA1 expression more broadly, and
whether combination therapy to ameliorate possible statin-
induced ABCA1 downregulation is suitable.
LXR agonists
Given that the LXR transcription factor is a potent
inducer of ABCA1 expression coupled with evidence of
anti-inflammatory impact [11], it follows that LXR ago-
nists would be strong candidates as potential therapeu-
tics for treatment of inflammatory lung disease. This
was supported by recent studies using intranasal admin-
istration of LXR agonists (T0901317 or GW3965) that
showed significant attenuation of pro-inflammatory
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cytokines in mice in vivo and lung epithelial cells
in vitro [114, 115]. However, as outlined, currently avail-
able LXR ligands target both LXR isoforms, leading to
undesirable side effects on lipid parameters [116, 117].
These include increased plasma fatty acid and triglycer-
ides, which are known risk factors of COPD [118–120].
Early LXR agonists, such as GW3965, have also failed to
completely repress inflammatory cytokine production
from alveolar macrophages in vitro [121]. The adverse
effects of synthetic LXR agonist treatment, including ele-
vated triglyceride levels and hepatoxicity, are thought
due to LXRα activation [117]. Thus, development of
LXRβ-selective agonists are currently under clinical in-
vestigation to mitigate against hepatic lipogenesis.
Conclusions
In recent years, our understanding of the role and function
of ABCA1 has evolved from the traditional function in
maintaining cellular cholesterol homeostasis to include its
potent anti-inflammatory function. This has led to the pos-
sibility of exploiting known and novel signaling pathways to
upregulate ABCA1 expression in a number of chronic
disease settings. Notably, signaling pathways implicated in
inflammatory responses are responsible for regulating
ABCA1 (transcriptionally or post-translationally) and its
ability to repress inflammation exists. Currently unknown
is the extent of the therapeutic benefit that may be achieved
by targeting ABCA1 in inflammatory lung diseases like
COPD. Despite the primary focus on the potential of
ABCA1 as a therapeutic target in atherosclerosis, its dual
role in repressing inflammation while maintaining choles-
terol homeostasis represents a promising therapeutic target
for inflammatory lung diseases in the future.
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